Moxifloxacin Pharmathen (Moxifloxacin)

• Moxifloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections of the respiratory tract and skin.
• Community‑acquired bacterial pneumonia: achieves clinical cure and bacterial eradication in adult patients.
• Acute bacterial sinusitis: resolves infection and relieves sinus inflammation.
• Acute bacterial exacerbation of chronic bronchitis: improves lung function and reduces bacterial load.
• Complicated skin and skin‑structure infections: provides rapid bacterial clearance and promotes wound healing.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, it prevents the supercoiling and separation of DNA strands, leading to inhibition of bacterial cell division and ultimately bacterial cell death. This bactericidal activity is broad‑spectrum against Gram‑positive, Gram‑negative and atypical respiratory pathogens.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: transient gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: mild to moderate intensity.
• Rash: skin erythema or pruritus.
• Elevated liver enzymes: transient increase in transaminases.
• Vomiting: occasional emesis.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate torsades de pointes.
• Clostridioides difficile infection: severe colitis after antibiotic exposure.
• Severe allergic reactions: anaphylaxis, angioedema.
• Hepatic failure: rare but potentially fatal liver injury.
• Seizures: lowered seizure threshold in predisposed patients.

• Moxifloxacin requires careful assessment of patient risk factors before use.
• Renal impairment: adjust therapy based on renal function and monitor for accumulation.
• History of tendon disorders: avoid use due to increased risk of tendon rupture.
• QT prolongation: obtain baseline ECG and monitor in patients with cardiac risk.
• Concomitant QT‑prolonging drugs: avoid combination to reduce arrhythmia risk.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several medicines, altering safety or efficacy.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: additive toxicity.
• Concurrent use of drugs that prolong QT interval (e.g., quinidine, macrolides): heightened arrhythmia risk.
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.
• Antacids containing aluminum or magnesium (IV formulation less affected but caution advised): may reduce drug stability.
• Rifampin: may decrease moxifloxacin plasma concentrations.

Moderate Interactions (Monitor Closely)

• Corticosteroids: increased risk of tendon rupture.
• NSAIDs: may potentiate central nervous system adverse effects.
• Theophylline: possible increase in plasma levels leading to toxicity.
• Cyclosporine: may raise moxifloxacin concentrations.
• Digoxin: monitor serum levels for potential increase.